超声引导下微波消融与手术治疗单发T1bN0M0甲状腺乳头状癌:一项前瞻性多中心研究
该前瞻性多中心研究纳入10家医院123例连续单发T1bN0M0甲状腺乳头状癌患者,按意愿分为微波消融组52例和手术组71例,随访约10个月。微波消融组与手术组在局部进展、新发甲状腺癌及远处转移方面均无发生,淋巴结转移率分别为5.8%和1.4%(p=0.177),并发症率分别为9.6%和11.3%(p=0.27),微波消融组美容效果更优(p<0.01)。作者认为微波消融短期疗效与手术相当,可能成为低危T1bN0M0甲状腺乳头状癌的可选选择,但淋巴结转移问题需进一步研究。
要点
- 微波消融组与手术组淋巴结转移率分别为5.8%和1.4%,差异无统计学意义(p=0.177)。
- 两组均无局部肿瘤进展、新发甲状腺癌或远处转移发生。
- 微波消融组美容效果优于手术组(p<0.01),并发症率分别为9.6%和11.3%(p=0.27)。
核心结论
- 微波消融治疗T1bN0M0甲状腺乳头状癌的短期疗效与手术相当,可能成为低危患者手术的可选替代,但淋巴结转移问题需进一步研究。
研究设计与样本
- 前瞻性多中心研究,2019年12月至2021年4月从10家医院纳入123例连续单发T1bN0M0甲状腺乳头状癌无淋巴结转移或远处转移患者,按患者意愿分为微波消融组52例和手术组71例。
诊断标准与关键数值
- 微波消融组淋巴结转移率5.8%,手术组1.4%(p=0.177),差异无统计学意义。
- 微波消融组并发症率9.6%(5/52),手术组11.3%(8/71),p=0.27。
- 微波消融组美容效果优于手术组(p<0.01)。
- 两组随访时间分别为10.6±4.2个月和10.4±3.4个月。
临床应用与阅片要点
- 作者认为微波消融可能作为低危T1bN0M0甲状腺乳头状癌手术的可选选择,但淋巴结转移问题需进一步研究。
- 原文未据此给出其他临床推荐。
局限性
- 原文结论指出对淋巴结转移的担忧需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Microwave ablation (MWA) has emerged as a minimally invasive technology for papillary thyroid microcarcinoma (PTMC), but it has not been widely applied to treat T1bN0M0 PTC with high-level evidence. This study was designed to compare the real-world efficacy and safety of MWA or surgery for treating T1bN0M0 PTC.
METHODS: From December 2019 to April 2021, 123 continuous unifocal T1bN0M0 PTC patients without lymph node metastasis (LNM) or distant metastasis (DM) were included from 10 hospitals. Patients were allocated into the MWA or surgery group based on their willingness. The main outcomes were local tumour progression (LTP), new thyroid cancer, LNM, and DM. The secondary outcomes included changes in tumour size and volume, complications, and cosmetic results. Subgroup analyses were conducted to identify influencing factors.
RESULTS: Fifty-two patients chose MWA, and 71 patients chose surgery. Patients had similar demographic information and tumour characteristics in the two groups. The follow-up durations after MWA and surgery were 10.6 ± 4.2 and 10.4 ± 3.4 months, respectively. The LNM rate was 5.8% in the MWA group and 1.4% in the surgery group (p = 0.177). No LTP, new thyroid cancer, or distant metastasis (DM) occurred in either group. Five (9.6%) of the 52 patients in the MWA group and 8 (11.3%) of the 71 patients in the surgery group had complications (p = 0.27). Better cosmetic results were found in the MWA group (p < 0.01).
CONCLUSION: MWA achieved comparable short-term treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC but concerns about LNM need to be studied further.
CLINICAL RELEVANCE STATEMENT: MWA achieved comparable short-time treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC.
KEY POINTS: • MWA achieved comparable short-term treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC but concerns about LNM need to be studied further. • The complication rate in the surgery group was higher than that in the MWA group without a significant difference. • There was no statistically significant difference in the LNM rate between the MWA and surgery groups.
引用
- Guo MH, Dou JP, Zheng L, et al. Ultrasound-guided microwave ablation versus surgery for solitary T1bN0M0 papillary thyroid carcinoma: a prospective multicenter study. Eur Radiol. 2023. PMID: 37548692. doi:10.1007/s00330-023-09908-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。